Results from two early phase clinical trials suggest that patients with advanced lung cancer may have new treatment options that improve their survival. The results were reported recently at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer in Coronado, CA.

The findings, said Dr. Paul Bunn of the University of Colorado and a leading expert on lung cancer treatment, are part of an encouraging trend. “Almost every year now we’re getting new drugs that improve survival in lung cancer patients,” he said during a press briefing. “But we have a long way to go.”